Amyloidosis, BiovelocITA invests in Amypopharma
BiovelocITA, the first Italian accelerator dedicated to biotech companies, is investing 680,000 euro in Amypopharma, a spin-off from University of Milano-Bicocca, which develops innovative therapies for the treatment of amyloidosis.
The investment follows the signing of a Licence Agreement between University of Milano-Bicocca and Amypopharma concerning the patent portfolio relating to nanoparticles for the treatment of Alzheimer’s disease, including the “ABeta” and “Liposomes” families, as well as the Amyposomes® registered trademark.
This agreement made it possible to make an investment in the development of innovative therapies for the treatment of amyloidosis. As part of the plan, Amypopharma will have non-exclusive use of certain university areas at reduced rates for three years.
“The mission of BiovelocITA is to create a bridge that is able to link the world of research with that of industry, identifying promising discoveries with potentially exceptional results and turning them into real industrial projects”, said Marco Sardina, Chief Scientific Officer at BiovelocITA.
“With Amypopharma, medical science can make an important step on the path towards amyloidosis therapy”, said Gabriella Camboni, CEO of BiovelocITA. “Amypopharma must continue without delay along the path traced out in the laboratory to be able to turn its studies into practical clinical application”.